CTNM

Contineum Therapeutics, Inc. (NASDAQ:CTNM) is a clinical-stage biopharmaceutical company founded in 2009 and headquartered in San Diego, California. Originally incorporated as Pipeline Therapeutics, Inc., the company rebranded to Contineum Therapeutics in November 2023. The company focuses on developing novel oral small molecule therapies targeting neurological, inflammatory, and immunological conditions with significant unmet medical needs. As a pre-revenue biotech firm, Contineum is advancing multiple drug candidates through various stages of clinical development, with its lead asset targeting both pulmonary fibrosis and multiple sclerosis.